ASH regularly produces educational webinars, video series, and podcasts that feature presentations by experts in the field, cover current information on how to best diagnose and care for patients, and topical discussion on issues relevant to hematology. This content is free to stream on ASH On Demand.
On October 14, 2016, the Centers for Medicare and Medicaid Services (CMS) released its final rule (regulation) outlining the new payment system for Medicare clinicians, implementing the Merit-Based Incentive Payment System (MIPS) and Alternative Payment Model (APM) payment provisions of the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). This webinar provides an overview of the final rule and its impact on hematology, as well as outlines the compliance implications for ASH’s clinical practice members.
Joseph Alvarnas, MD, City of Hope National Medical Center, Duarte, CA
Erika Miller, JD, Cavarocchi – Ruscio – Dennis Associates, LLC, Washington, DC
The ASH Meeting on Hematologic Malignancies includes five core malignant hematology themes: leukemia, lymphoma, myelodysplastic syndromes, myeloproliferative neoplasm, and myeloma. This Focus on Lymphoma webinar features a discussion with two clinicians in the area of Lymphoma regarding how clinical practice has evolved in recent years, as well as discussion of important conclusions from the previous year’s meeting. The doctors also discuss what to expect in the coming year, with emphasis on how "How I Treat" is a different approach than the classic format of educational and or scientific sessions.
The next ASH Meeting on Hematologic Malignancies will be held in Chicago, IL, September 8-9, 2017. The program’s “How I Treat” presentations showcase speakers’ evidence-based treatment approaches, identify cutting-edge scientific data that can be translated into new strategies for diagnosis and treatment, and address what to do in cases where there is no data. This meeting is a unique opportunity to join colleagues and top experts in treatment of hematologic malignancies in an intimate, smaller-meeting setting and discuss the latest drug developments and most relevant research findings advancing patient care today. Visit www.hematology.org/malignancies for information related to next year’s meeting!
Joseph Connors, MD, BC Cancer Agency Centre for Lymphoid Cancer, Vancouver, BC
Jonathan W. Friedberg, MD, MMSc, Wilmot Cancer Institute, University of Rochester, Rochester, NY
"Still haven't registered for the 2016 ASH Meeting on Hematologic Malignancies? Join us for this special webinar preview of what will be presented next month! Listen to three program speakers as they give you an exclusive sneak-peek into what they will present at the meeting. Then participate in a special Q&A session to find out why you should join us in Chicago in September!
This webinar will feature a special preview of presentations by three distinguished presenters from the upcoming meeting, structured in the \"How I Treat\" format to best convey how you can immediately apply evidenced-based treatment approaches to practice:
Dr. David Steensma: How I treat lower-risk myelodysplastic syndromes (MDS)
Dr. Ruben Mesa: How I Treat Myelofibrosis Patients Who Have Failed Ruxolitinib
Dr. John P. Leonard: How I Treat Diffuse Large B-Cell and Mediastinal Large Cell Lymphomas
The ASH Meeting on Hematologic Malignancies, will be held in Chicago, IL, September 16-17. This meeting is a unique opportunity to join colleagues and top experts in treatment of hematologic malignancies in an intimate, smaller-meeting setting and discuss the latest drug developments and most relevant research findings advancing patient care today. Visit www.hematology.org/malignancies to review speaker line-up and program schedule and to register.
This webinar discusses the FDA accelerated approval of nivolumab for the treatment of patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and post-transplantation brentuximab vedotin. The approval was based on two single-arm, multicenter trials of nivolumab in adults with relapsed or refractory cHL. The trials enrolled patients regardless of PD-L1 expression status on Reed-Sternberg cells. The primary efficacy endpoint was objective response rate (ORR) as determined by an independent radiographic review committee. Additional outcome measures included duration of response (DOR).
Wyndham Wilson, MD, PhD, Center for Cancer Research, National Cancer Institute, Bethesda, MD
Yvette L. Kasamon, MD, Division of Hematology Products, Office of Hematology and Oncology Products, U.S. Food and Drug Administration, Silver Spring, MD
Stephen Ansell, MD, PhD, Professor of Medicine, Chair, Lymphoma Group, Mayo Clinic, Rochester, MN
This webinar discusses the FDA's accelerated approval of venetoclax for the treatment of people with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy, including those with 17p deletion. Venetoclax is a small molecule inhibitor of the BCL-2 protein and was granted Breakthrough Therapy Designation by the FDA in April 2015 for the treatment of people with previously treated (relapsed or refractory) CLL with 17p deletion.
Grzegorz S. Nowakowski, MO, Division of Hematology, Mayo Clinic, Rochester, MN
Lori Ehrlich, MD, Division of Hematology Products, Office of Hematology and Oncology Products, U.S. Food and Drug Administration, Silver Spring, MD
Richard R. Furman, MD, Department of Hematology/Oncology, Weill Cornell Medical College, New York, NY
This webinar will discuss the FDA approval of Ixazomib in combination with two other therapies to treat people with multiple myeloma (a form of blood cancer found in the bone marrow) who have received at least one prior therapy. Ixazomib is the first oral proteasome inhibitor and is approved in combination with lenalidomide and dexamethasone (a type of corticosteroid).
David Steensma, MD, Dana-Farber Cancer Institute, Division of Hematological Malignancies, Boston, MA
Alexandria Schwarsin, MD, Medical Officer, U.S. Food and Drug Administration, Silver Spring, MD
S. Vincent Rajkumar, MD, Edward W. and Betty Knight Scripps Professor of Medicine, Division of Hematology, Mayo Clinic, Rochester, MN
This webinar discusses the FDA's accelerated approval of daratumumab to treat patients with multiple myeloma who have received at least three prior treatments. Daratumumab is the first monoclonal antibody approved for treating multiple myeloma.
Mikkael Sekeres, MD, Director, Leukemia Program, Professor of Medicine, Cleveland Clinic, Cleveland, OH
Nicole Gormley, MD, Acting Clinical Team Lead, Scientific Liaison for Multiple Myeloma, Division of Hematology Products, U.S. Food and Drug Administration, Silver Spring, MD
Paul G. Richardson, MD, RJ Corman Professor of Medicine, Harvard Medical School, Clinical Program Leader, Director of Clinical Research, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA
This webinar recording discusses the FDA approval of von Willebrand factor (Recombinant), for use in adults 18 years of age and older who have von Willebrand disease (VWD). This is the first FDA-approved recombinant von Willebrand factor for the on-demand (as needed) treatment and control of bleeding episodes in adults diagnosed with VWD.
Paula James, MD, FRCPC, Professor, Department of Medicine, Queen's University, Kingston, Ontario
Victor Baum, MD, Division of Hematology Clinical Review, U.S. Food and Drug Administration, Silver Spring, MD; Adjunct Professor of Anesthesiology & Pediatrics, George Washington Univ. School of Medicine
Margaret V. Ragni, MD, MPH, Professor of Medicine and Clinical Translational Science, University of Pittsburgh Medical Center, Director, Hemophilia Center of Western PA, Pittsburgh, PA
This webinar recording discusses the U. S. Food and Drug Administration's accelerated approval of idarucizumab for the treatment of patients given dabigatran when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures, or in life-threatening or uncontrolled bleeding.
Jack Ansell, MD, Professor of Medicine, Hofstra North Shore/LIJ School of Medicine, New York, NY
Edvardas Kaminskas, MD, Deputy Director, Division of Hematology Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD
Ken Bauer, MD, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Jennifer Woyach, MD, discusses the latest drug treatments for CLL patients. Dr. Woyach presented on the topic at the 2015 ASH Annual Meeting in a session titled "New Approaches in Chronic Lymphocytic Leukemia and Prolymphocytic Leukemia."